Xtl Biopharmaceuticals Stock Gross Profit
| XTLB Stock | ILS 6.40 0.20 3.03% |
XTL Biopharmaceuticals fundamentals help investors to digest information that contributes to XTL Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of XTL Stock. The fundamental analysis module provides a way to measure XTL Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTL Biopharmaceutica stock.
XTL |
XTL Biopharmaceuticals Company Gross Profit Analysis
XTL Biopharmaceutica's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, XTL Biopharmaceuticals reported 0.0 of gross profit. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Gross Profit (which currently averages 0.0) industry. This indicator is about the same for all Israel stocks average (which is currently at 0.0).
XTL Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XTL Biopharmaceutica's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XTL Biopharmaceutica could also be used in its relative valuation, which is a method of valuing XTL Biopharmaceutica by comparing valuation metrics of similar companies.XTL Biopharmaceutica is currently under evaluation in gross profit category among its peers.
XTL Fundamentals
| Return On Equity | 0.38 | |||
| Return On Asset | -0.1 | |||
| Current Valuation | 61.84 M | |||
| Shares Outstanding | 514.21 M | |||
| Shares Owned By Insiders | 16.20 % | |||
| Price To Earning | 558.33 X | |||
| EBITDA | (940 K) | |||
| Net Income | 435 K | |||
| Cash And Equivalents | 5.06 M | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 51.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.05 M) | |||
| Beta | 1.03 | |||
| Market Capitalization | 236.53 K |
About XTL Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTL Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTL Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTL Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in XTL Stock
XTL Biopharmaceutica financial ratios help investors to determine whether XTL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTL with respect to the benefits of owning XTL Biopharmaceutica security.